Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on the Annual General Meeting of Shareholders held on July 26, 2021. Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, filed this report to disclose the approval of all proposed resolutions by its shareholders.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder approvals rather than financial performance data.
Material Changes and Corporate Actions
Shareholders approved the following key resolutions:
- Auditor Appointment: Reappointed Kesselman & Kesselman (PwC network) as auditors for 2021.
- Board Composition: Re-elected Ofer Tsimchi and Eric Swenden; elected Alessandro Della Chà to the Board of Directors for three-year terms ending in 2024.
- Compensation and Policy: Approved amendments to the Compensation Policy, Letters of Exemption and Indemnification, and the Amended and Restated Award Plan (2010).
- Executive Compensation: Approved an annual bonus and salary increase for Chief Commercial Officer Rick D. Scruggs, along with amended employment terms for Mr. Scruggs and Dr. June Almenoff.
- Equity Grants: Approved grants of options to purchase American Depository Shares (ADSs) to directors, Mr. Rick D. Scruggs, Mr. Dror Ben-Asher, and additional U.S. directors.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder meeting outcomes.
Key Facts for Investor Verification
- Verify the specific terms of the new employment agreements for Mr. Rick D. Scruggs and Dr. June Almenoff.
- Confirm the number of options granted and the exercise price for the new equity awards to directors and executives.
- Review the details of the amended Compensation Policy and Award Plan (2010) for potential dilution impacts.
- Check the aggregate compensation paid to auditors for the year ended December 31, 2020, as referenced in the auditor appointment resolution.